ARIAD Pharmaceuticals All Financial Data in US $ (mln)

Company News

ARIAD to Present at the RBC Capital Markets Healthcare Conference
ARIAD Pharmaceuticals (February 10, 2016)
The Medicines Company Appoints Alexander J. Denner, Ph.D. to its Board of Directors
The Medicines Company (February 03, 2016)
ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2015 Financial Results
ARIAD Pharmaceuticals (February 02, 2016)
ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788
ARIAD Pharmaceuticals (February 01, 2016)
ARIAD Reports Inducement Grant to New Chief Executive Officer
ARIAD Pharmaceuticals (January 15, 2016)
ARIAD Announces Termination of Shareholder Rights Plan
ARIAD Pharmaceuticals (January 11, 2016)
ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors
ARIAD Pharmaceuticals (January 10, 2016)
ARIAD and Otsuka Submit New Drug Application in Japan for Ponatinib
ARIAD Pharmaceuticals (January 08, 2016)
ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
ARIAD Pharmaceuticals (December 18, 2015)
ARIAD Announces Pricing and Reimbursement Negotiations for Iclusig in France to Continue into 2016
ARIAD Pharmaceuticals (December 11, 2015)

Displaying 10 out of a possible 861 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile ARIAD Pharmaceuticals (ARIA) is a Massachusetts based biotechnology company focused on development & marketing of anti-cancer drugs that function by regulating the cell signalling pathways.
Listed or Private Company Listed
Company Classification Biotechnology; Genomics
Country USA
Company Website Website
Technology Platform Profile
Full Company Profile Information

PARTNERING OPPORTUNITIES (Click on Product Name for Full Details)

ProductProduct Available for Partnering Opportunity Comment Available USA Available Europe Available Japan Available RoW Markets Detail
Iclusig Yes Company plans for commercialisation of ponatinib on its own in US & potentially in Europe and a regional partnership for the product in select ex-US markets. No Yes Yes Yes WW ex USA
Brigatinib Yes FEB15 Seeking partners for further development. Yes Yes Yes Yes Market undisclosed

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
02/09/2015 2 Sep: Bloomberg reports that Baxalta has abandoned its $2bn bid to acquire the company. 1,426 -17.0% -292

Top 3 Products (Worldwide Sales)

Annual Sales WW - Sales Growth per Year (%)
Rank1 ProductProduct Generic NameGeneric Name Therapeutic Subcategory 2012 2013 2013
1 Iclusig ponatinib hydrochloride Other cytostatics - 452 n/a
Note: Shaded Cells3

RX Sales Chart

ARIAD Pharmaceuticals Data Growth
2012 2013 2013
 Revenues By Segment
     Pharmaceuticals Sales (In-depth)
       Rx & OTC Pharmaceuticals
         Prescription (Rx) Pharmaceuticals - 45 -

Therapy Area Focus

ARIAD Pharmaceuticals
 WW Rx & OTC Sales By Therapy Area
  Main Categories
     Oncology & Immunomodulators 45
     Other Rx & OTC Pharma 0

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
ARIAD Pharmaceuticals 4 42


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

EP Vantage - last 6 months
Interview – Bellicum takes on the suicide switch wannabes (November 20, 2015)
The defensive anti-chain engulfs Ariad (September 01, 2015)

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now